Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment.
Cancer Lett
; 598: 217095, 2024 Aug 28.
Article
in En
| MEDLINE
| ID: mdl-38964728
ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) constitutes a significant global cancer burden, given its high prevalence and associated mortality. Despite substantial progress in survival rates due to the enhanced multidisciplinary approach to treatment, these methods often lead to severe tissue damage, compromised function, and potential toxicity. Thus, there is an imperative need for novel, effective, and minimally damaging treatment modalities. Neoadjuvant treatment, an emerging therapeutic strategy, is designed to reduce tumor size and curtail distant metastasis prior to definitive intervention. Currently, neoadjuvant chemotherapy (NACT) has optimized the treatment approach for a subset of HNSCC patients, yet it has not produced a noticeable enhancement in overall survival (OS). In the contemporary cancer therapeutics landscape, immunotherapy is gaining traction at an accelerated pace. Notably, neoadjuvant immunotherapy (NAIT) has shown promising radiological and pathological responses, coupled with encouraging efficacy in several clinical trials. This potentially paves the way for a myriad of possibilities in treatment de-escalation of HNSCC, which warrants further exploration. This paper reviews the existing strategies and efficacies of neoadjuvant immune checkpoint inhibitors (ICIs), along with potential de-escalation strategies. Furthermore, the challenges encountered in the context of the de-escalation strategies of NAIT are explored. The aim is to inform future research directions that strive to improve the quality of life (QoL) for patients battling HNSCC.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoadjuvant Therapy
/
Squamous Cell Carcinoma of Head and Neck
/
Immune Checkpoint Inhibitors
/
Head and Neck Neoplasms
/
Immunotherapy
Limits:
Humans
Language:
En
Journal:
Cancer Lett
/
Cancer lett
/
Cancer letters
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
Irlanda